Marksans Pharma Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹102.65
- Today's High:
- ₹109
- Open Price:
- ₹109
- 52W Low:
- ₹45.395
- 52W High:
- ₹122.5
- Prev. Close:
- ₹106
- Volume:
- 447354
Company Statistics
- Market Cap.:
- ₹20.73 billion
- Book Value:
- 17.612
- Revenue TTM:
- ₹13.20 billion
- Operating Margin TTM:
- 18.23%
- Gross Profit TTM:
- ₹5.81 billion
- Profit Margin:
- 13.06%
- Return on Assets TTM:
- 16.17%
- Return on Equity TTM:
- 25.47%
Company Profile
Marksans Pharma Limited had its IPO on under the ticker symbol 524404.
The company operates in the Healthcare sector and Drug Manufacturers - Major industry. Marksans Pharma Limited has a staff strength of 1,150 employees.
Stock update
Shares of Marksans Pharma Limited opened at ₹109 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹102.65 - ₹109, and closed at ₹105.9.
This is a -0.09% slip from the previous day's closing price.
A total volume of 447,354 shares were traded at the close of the day’s session.
In the last one week, shares of Marksans Pharma Limited have slipped by -3.86%.
Marksans Pharma Limited's Key Ratios
Marksans Pharma Limited has a market cap of ₹20.73 billion, indicating a price to book ratio of 2.7521 and a price to sales ratio of 1.5287.
In the last 12-months Marksans Pharma Limited’s revenue was ₹13.20 billion with a gross profit of ₹5.81 billion and an EBITDA of ₹2.79 billion. The EBITDA ratio measures Marksans Pharma Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Marksans Pharma Limited’s operating margin was 18.23% while its return on assets stood at 16.17% with a return of equity of 25.47%.
In Q3, Marksans Pharma Limited’s quarterly earnings growth was a positive 92.1% while revenue growth was a positive 39%.
Marksans Pharma Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 12.051
- PEG
Its diluted EPS in the last 12-months stands at ₹4.243 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Marksans Pharma Limited’s profitability.
Marksans Pharma Limited stock is trading at a EV to sales ratio of 1.4354 and a EV to EBITDA ratio of 7.0213. Its price to sales ratio in the trailing 12-months stood at 1.5287.
Marksans Pharma Limited stock pays annual dividends of ₹0.1 per share, indicating a yield of 0.2% and a payout ratio of 3.36%.
Balance sheet and cash flow metrics
- Total Assets
- ₹21.90 billion
- Total Liabilities
- ₹3.41 billion
- Operating Cash Flow
- ₹-2592120000.00
- Capital Expenditure
- ₹536.31 million
- Dividend Payout Ratio
- 3.36%
Marksans Pharma Limited ended 2024 with ₹21.90 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹21.90 billion while shareholder equity stood at ₹17.45 billion.
Marksans Pharma Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.41 billion in other current liabilities, 453160000.00 in common stock, ₹17.00 billion in retained earnings and ₹384.89 million in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹7.19 billion. The company’s total short-term debt was ₹415,880,000 while long-term debt stood at ₹0.
Marksans Pharma Limited’s total current assets stands at ₹16.75 billion while long-term investments were ₹0 and short-term investments were ₹41.95 million. Its net receivables were ₹4.17 billion compared to accounts payable of ₹0 and inventory worth ₹4.85 billion.
In 2024, Marksans Pharma Limited's operating cash flow was ₹-2592120000.00 while its capital expenditure stood at ₹536.31 million.
Comparatively, Marksans Pharma Limited paid ₹0.03 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹105.9
- 52-Week High
- ₹122.5
- 52-Week Low
- ₹45.395
- Analyst Target Price
- ₹
Marksans Pharma Limited stock is currently trading at ₹105.9 per share. It touched a 52-week high of ₹122.5 and a 52-week low of ₹122.5. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹109.11 and 200-day moving average was ₹80.5 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5145% of the company’s stock are held by insiders while 227.1% are held by institutions.
Frequently Asked Questions About Marksans Pharma Limited
Similar Industry Stocks (Drug Manufacturers - Major)
Most Active
Top Gainers
Top Losers
About
Marksans Pharma Limited, together with its subsidiaries, researches, develops, manufactures, markets, distributes, and sells generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the analgesic, anti-inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, pain management, neurology, antacid, hormonal, antifungal, antiulcerative, cardiovascular and central nervous system, vitamin, cough and cold, dermatology, gastrointestinal, gynecology, cephalosporin, injectable, antibacterial, hypertension, oncology, and antibiotics and anti-allergic therapeutic areas. It also provides contract research and manufacturing services; and develops and out-licenses patented products. The company was incorporated in 1992 and is headquartered in Mumbai, India.